Studying rare neuromuscular disorders has long been a challenge for scientists. With few patients and limited biological samples, progress was slow and treatments rare. Now, the EU-funded DREAMS project is changing the landscape by using iPSC models, stem-cell systems that recreate disease biology in the lab, to revolutionise neuromuscular research.
The project’s name says it all: Drug Repurposing with Artificial Intelligence for Muscular disorders (DREAMS). Led by the CECS/I-Stem Institute (Centre d’Études des Cellules Souches) in France and supported by eight other partners across Europe, DREAMS uses advanced stem-cell science and artificial intelligence to speed up the discovery of safer, more effective therapies for rare neuromuscular diseases.
From a Drop of Blood to a Living iPSC Model
The story begins with a single blood or skin cell. Through cutting-edge reprogramming techniques, researchers transform these samples into induced pluripotent stem cells (iPSCs) — versatile cells capable of becoming almost any tissue type.
Within DREAMS, these iPSCs are turned into skeletal muscle cells that mimic the exact genetic and molecular features of patients’ diseases. These iPSC models allow scientists to study disease mechanisms directly in human cells, bypassing animal testing and opening a window into how neuromuscular disorders develop.
Learn more about our stem-cell innovation approach
Using iPSC Models to Reveal Disease Mechanisms
In the lab, DREAMS scientists use these iPSC-based muscle assays to investigate how muscle cells behave under disease conditions. They can observe cell degeneration, protein disorganisation, or metabolic changes, crucial clues that reveal how each disorder functions at the molecular level.
This deep biological insight helps researchers identify common therapeutic targets shared across different neuromuscular diseases, laying the foundation for new treatments that could help several patient groups at once.
AI and iPSC Models: A New Era for Drug Discovery
DREAMS integrates artificial intelligence (AI) to analyse the massive amount of data generated by its iPSC models. The AI platform, developed by project partner Kantify, detects patterns invisible to the human eye and predicts how cells might respond to thousands of potential compounds.
This combination of AI and stem-cell data reduces the cost and time of drug discovery and lowers the risk of toxicity or failure. It also makes the DREAMS platform reusable, so future projects can apply it to other rare diseases.
Five Diseases, One Shared Approach
DREAMS focuses on five rare neuromuscular diseases (NMDs) that share molecular mechanisms:
- Centronuclear myopathy (CNM)
- Duchenne muscular dystrophy (DMD)
- Emery-Dreifuss muscular dystrophy type 2 (EDMD2)
- Pompe disease (Glycogen Storage Disease type II)
- Danon disease
Although each condition affects patients differently, all involve defects in muscle cell organisation and energy processing. By studying them together through iPSC models, DREAMS aims to uncover treatments that can target common pathways and benefit multiple patient communities.
Adaptive Clinical Trials for Rare Diseases
Traditional clinical trials are difficult for rare diseases: too few patients, too many variables. DREAMS proposes a solution, adaptive trial design that evolves as results come in, developed with input from both patients and regulators.
This flexible model shortens the time from laboratory findings to validated therapies and ensures that every participant contributes meaningful data to the global effort against rare neuromuscular disorders.
A European Collaboration Driving Change
DREAMS unites nine partner organisations from six European countries with a total budget of €7.8 million and a duration of six years. Together, they combine the best of European expertise in cell biology, AI, and clinical science.
Beyond scientific progress, DREAMS contributes to society by:
- Improving the quality of life for patients living with rare neuromuscular diseases.
- Reducing healthcare costs through efficient drug repurposing.
- Creating a reusable platform for future rare disease research.
- Strengthening Europe’s innovation capacity in health and biotechnology.
Why iPSC Models Matter
iPSC models are transforming medicine. By turning human blood cells into functional muscle tissue, they allow scientists to explore disease biology in a way that is humane, personalised, and scalable.
Within DREAMS, they are the foundation of a new research ecosystem, one where biology and data meet to deliver hope faster to those who need it most.
